Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection

David Asmuth, Michael P. Busch, Megan E. Laycock, Beth A. Mohr, Leslie A. Kalish, Charles M. Van Der Horst

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Chronic infection with either hepatitis B (HBV) or hepatitis C virus (HCV) is frequently present in patients seropositive for human immunodeficiency virus (HIV) because of shared routes of transmission. With the advent of highly active antiretroviral therapy (HAART) regimens capable of controlling HIV replication and dramatically prolonging the survival of HIV-infected patients, the impact of co-morbid infections such as HBV and HCV has come into focus. Several studies have monitored HBV or HCV viral loads following initiation of HAART, with disparate results. The effects of HAART on hepatitis B and C plasma viral loads (n=9 and 32, respectively) and on liver enzyme levels were studied in a large cohort of prospectively studied subjects with advanced stage HIV disease. Comparing the mean pre- and post-HAART levels, there was an estimated increase of (a) 1.40 log10 from 4.83 to 6.24 log10 for HBV plasma viral load (P=0.07), (b) 0.74 log10 from 6.38 to 7.12 log 10 for HCV plasma viral load (P=0.001), and (c) 19.4 U/L from 37.4 to 56.8 U/L for serum alanine aminotransferase (P<0.001). While the number of subjects co-infected with HIV and HBV was limited, these data collected in a population of advanced stage HIV-infected patients raises questions regarding the interactions of these viruses with each other and the host immune system and has implications regarding the order in which antiviral therapies are initiated.

Original languageEnglish (US)
Pages (from-to)123-131
Number of pages9
JournalAntiviral Research
Volume63
Issue number2
DOIs
StatePublished - Aug 2004

Fingerprint

Highly Active Antiretroviral Therapy
Virus Diseases
Hepatitis C
Viral Load
Hepatitis B
HIV
Hepacivirus
Virus Replication
Alanine Transaminase
Coinfection
Alanine
Antiviral Agents
Immune System
Viruses
Survival
Liver
Enzymes
Infection
Serum
Population

Keywords

  • Antiretroviral therapy
  • Hepatitis B
  • Hepatitis C
  • Human immunodeficiency virus
  • Viral load

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection. / Asmuth, David; Busch, Michael P.; Laycock, Megan E.; Mohr, Beth A.; Kalish, Leslie A.; Van Der Horst, Charles M.

In: Antiviral Research, Vol. 63, No. 2, 08.2004, p. 123-131.

Research output: Contribution to journalArticle

Asmuth, David ; Busch, Michael P. ; Laycock, Megan E. ; Mohr, Beth A. ; Kalish, Leslie A. ; Van Der Horst, Charles M. / Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection. In: Antiviral Research. 2004 ; Vol. 63, No. 2. pp. 123-131.
@article{d236da6bbd2c4918ad224db333aaf60d,
title = "Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection",
abstract = "Chronic infection with either hepatitis B (HBV) or hepatitis C virus (HCV) is frequently present in patients seropositive for human immunodeficiency virus (HIV) because of shared routes of transmission. With the advent of highly active antiretroviral therapy (HAART) regimens capable of controlling HIV replication and dramatically prolonging the survival of HIV-infected patients, the impact of co-morbid infections such as HBV and HCV has come into focus. Several studies have monitored HBV or HCV viral loads following initiation of HAART, with disparate results. The effects of HAART on hepatitis B and C plasma viral loads (n=9 and 32, respectively) and on liver enzyme levels were studied in a large cohort of prospectively studied subjects with advanced stage HIV disease. Comparing the mean pre- and post-HAART levels, there was an estimated increase of (a) 1.40 log10 from 4.83 to 6.24 log10 for HBV plasma viral load (P=0.07), (b) 0.74 log10 from 6.38 to 7.12 log 10 for HCV plasma viral load (P=0.001), and (c) 19.4 U/L from 37.4 to 56.8 U/L for serum alanine aminotransferase (P<0.001). While the number of subjects co-infected with HIV and HBV was limited, these data collected in a population of advanced stage HIV-infected patients raises questions regarding the interactions of these viruses with each other and the host immune system and has implications regarding the order in which antiviral therapies are initiated.",
keywords = "Antiretroviral therapy, Hepatitis B, Hepatitis C, Human immunodeficiency virus, Viral load",
author = "David Asmuth and Busch, {Michael P.} and Laycock, {Megan E.} and Mohr, {Beth A.} and Kalish, {Leslie A.} and {Van Der Horst}, {Charles M.}",
year = "2004",
month = "8",
doi = "10.1016/j.antiviral.2004.03.006",
language = "English (US)",
volume = "63",
pages = "123--131",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection

AU - Asmuth, David

AU - Busch, Michael P.

AU - Laycock, Megan E.

AU - Mohr, Beth A.

AU - Kalish, Leslie A.

AU - Van Der Horst, Charles M.

PY - 2004/8

Y1 - 2004/8

N2 - Chronic infection with either hepatitis B (HBV) or hepatitis C virus (HCV) is frequently present in patients seropositive for human immunodeficiency virus (HIV) because of shared routes of transmission. With the advent of highly active antiretroviral therapy (HAART) regimens capable of controlling HIV replication and dramatically prolonging the survival of HIV-infected patients, the impact of co-morbid infections such as HBV and HCV has come into focus. Several studies have monitored HBV or HCV viral loads following initiation of HAART, with disparate results. The effects of HAART on hepatitis B and C plasma viral loads (n=9 and 32, respectively) and on liver enzyme levels were studied in a large cohort of prospectively studied subjects with advanced stage HIV disease. Comparing the mean pre- and post-HAART levels, there was an estimated increase of (a) 1.40 log10 from 4.83 to 6.24 log10 for HBV plasma viral load (P=0.07), (b) 0.74 log10 from 6.38 to 7.12 log 10 for HCV plasma viral load (P=0.001), and (c) 19.4 U/L from 37.4 to 56.8 U/L for serum alanine aminotransferase (P<0.001). While the number of subjects co-infected with HIV and HBV was limited, these data collected in a population of advanced stage HIV-infected patients raises questions regarding the interactions of these viruses with each other and the host immune system and has implications regarding the order in which antiviral therapies are initiated.

AB - Chronic infection with either hepatitis B (HBV) or hepatitis C virus (HCV) is frequently present in patients seropositive for human immunodeficiency virus (HIV) because of shared routes of transmission. With the advent of highly active antiretroviral therapy (HAART) regimens capable of controlling HIV replication and dramatically prolonging the survival of HIV-infected patients, the impact of co-morbid infections such as HBV and HCV has come into focus. Several studies have monitored HBV or HCV viral loads following initiation of HAART, with disparate results. The effects of HAART on hepatitis B and C plasma viral loads (n=9 and 32, respectively) and on liver enzyme levels were studied in a large cohort of prospectively studied subjects with advanced stage HIV disease. Comparing the mean pre- and post-HAART levels, there was an estimated increase of (a) 1.40 log10 from 4.83 to 6.24 log10 for HBV plasma viral load (P=0.07), (b) 0.74 log10 from 6.38 to 7.12 log 10 for HCV plasma viral load (P=0.001), and (c) 19.4 U/L from 37.4 to 56.8 U/L for serum alanine aminotransferase (P<0.001). While the number of subjects co-infected with HIV and HBV was limited, these data collected in a population of advanced stage HIV-infected patients raises questions regarding the interactions of these viruses with each other and the host immune system and has implications regarding the order in which antiviral therapies are initiated.

KW - Antiretroviral therapy

KW - Hepatitis B

KW - Hepatitis C

KW - Human immunodeficiency virus

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=4043106332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043106332&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2004.03.006

DO - 10.1016/j.antiviral.2004.03.006

M3 - Article

C2 - 15302141

AN - SCOPUS:4043106332

VL - 63

SP - 123

EP - 131

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 2

ER -